

## Marc Recht

Partner



mrecht@cooley.com

+1 617 937 2316

Boston

Capital Markets  
Life Sciences  
Mergers and Acquisitions  
Emerging Companies  
Medtech  
Digital Health  
Venture Capital  
Biotechnology  
CooleyREG  
France

Marc is co-head of Cooley's global life sciences practice and an internationally recognized corporate lawyer with deep experience in the life sciences and biotechnology sectors. He represents a range of public and private companies and investors, advising on all manner of corporate, fundraising and strategic transactions in the US and abroad.

In addition to his transactional practice, Marc regularly serves as an advisor to both US and foreign public life sciences companies and their boards on corporate governance, Securities and Exchange Commission (SEC) compliance, and complex disclosure matters. With more than 25 years of experience, he brings insight, judgment and a pragmatic approach to high-stakes decisions at every stage of a company's growth.

Marc played a central role in establishing and expanding Cooley's leadership in the UK and European biotech initial public offering (IPO) market. For more than a decade, he has helped make Cooley the go-to firm for transatlantic life sciences offerings, guiding dozens of companies through successful listings on Nasdaq.

### **Some of Marc's recent transactions include representing:**

#### *Capital markets*

- Morgan Stanley (lead underwriter): \$150 million (common stock) IPO for Talaris Therapeutics
- Valveva: \$170.6 million (American depositary shares and ordinary shares) US IPO and European private offering
- Keros Therapeutics: \$110.4 million (common stock) IPO
- Morgan Stanley (lead underwriter): \$75.2 million (common stock) IPO for Imara
- DBV Technologies: \$143 million (ADS) follow-on offering
- Jefferies (lead underwriter): \$103.5 million (common stock) IPO for Morphtic Therapeutic
- Prevail Therapeutics: \$125 million (common stock) IPO
- Milestone Pharmaceuticals: \$94.9 million (common stock) IPO
- DBV Technologies: \$81 million (ADS) follow-on offering
- Genfit: \$155.4 million (ordinary shares) IPO
- Avedro: \$70 million (common stock) IPO
- Jefferies (lead underwriter): \$86 million (common stock) IPO for Scholar Rock

- ERYTECH Pharma (France): \$144 million IPO
- Nightstar Therapeutics (UK): \$86 million IPO

#### *M&A and licensing/collaborations*

- Amolyt Pharma's sale to Alexion
- Checkpoint Therapeutics' sale to Sun Pharma
- Tectonic Therapeutic's merger with AVROBIO
- Avedro's sale to Glaukos
- Bidel's merger with Albireo
- Regado Biosciences' merger with Tobira Therapeutics

Before joining Cooley, Marc was a corporate partner at an international law firm. He has been recognized by Chambers USA in the Massachusetts Capital Markets category consistently since 2014. He also was recognized for his work in life sciences and healthcare by The Legal 500 in its 2013, 2016, 2020, 2024 and 2025 US editions, as well as for capital markets: equity offerings in its 2025 US edition. Additionally, Who's Who Legal named Marc a leading life sciences lawyer in its 2017 and 2018 editions.

While at Boston College Law School, Marc was the articles editor of the Third World Law Journal.

## Education

Boston College Law School  
JD, magna cum laude, 1999

Brandeis University  
BA, with honors, 1995

## Admissions & Credentials

Massachusetts

## Rankings & Accolades

Chambers USA: Life Sciences: Corporate/Commercial – Massachusetts (2025)

Chambers USA: Capital Markets – Massachusetts (2014 – 2025)

The Legal 500 US: Healthcare: Life Sciences (2013, 2016, 2020)

Who's Who Legal: Life Sciences (2017, 2018)

Super Lawyers: Rising Star (2007, 2010 – 2013)

Boston Business Journal: Biotech IPO (2015)